Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
Leukemia & Lymphoma|May 2, 2022
Rituximab, methotrexate, procarbazine and lomustine (R-MPL) for the treatment of primary Central nervous system lymphomaEyal Lebel, Neta Goldschmidt, Tali Siegal, et al.
Hematological Oncology|November 21, 2024
Ibrutinib With Bendamustine and Rituximab for Treatment of Patients With Relapsed/Refractory Aggressive B-Cell LymphomaMeirav Kedmi, Elena Ribakovsy, Ohad Benjamini, et al.
Haematologica|July 29, 2021
Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemiaOhad Benjamini, Lior Rokach, Gilad Itchaki, et al.
Leukemia & Lymphoma|June 23, 2025
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: a post hoc analysis of KEYNOTE-204 by prior lines of therapyJohn Kuruvilla, Dipenkumar Modi, Armando Santoro, et al.
British Journal of Haematology|June 8, 2017
Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patientsEldad J Dann, Osnat Bairey, Rachel Bar-Shalom, et al.
Blood|January 9, 2025
Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 studyMax S Topp, Matthew Matasar, John N Allan, et al.
Leukemia & Lymphoma|September 28, 2020
Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experienceYafit Segman, Elena Ribakovsky, Abraham Avigdor, et al.
The Lancet. Oncology|March 15, 2021
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 studyJohn Kuruvilla, Radhakrishnan Ramchandren, Armando Santoro, et al.
Annals of Hematology|January 27, 2022
Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL-a matched cohort analysisIrit Avivi, Chava Perry, Yafit Segman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2023
Genetic Characterization of Primary Mediastinal B-Cell Lymphoma: Pathogenesis and Patient OutcomesDaniel Noerenberg, Franziska Briest, Cornelius Hennch, et al.
Pageof 8